Press Releases

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Roswell Park Comprehensive Cancer Center has once again been named to Newsweek’s list of America’s Best Cancer Hospitals for 2025. Roswell Park has made the list every year since its inception in 2023.

An international clinical trial co-led by Roswell Park's Dr. Eunice Wang has demonstrated that the investigational drug ziftomenib can produce deep, durable responses in people with a specific biological subtype of acute myeloid leukemia (AML). Dr. Wang will present study findings at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

In talks at the annual meeting of the American Society of Clinical Oncology, experts from Roswell Park will give remarks on racial and ethnic disparities in outcomes among people with metastatic breast cancer; risk patterns for second cancers associated with human papillomavirus (HPV); and effects of immune checkpoint inhibitors (ICI) on cognitive function.

A meta-analysis led by Roswell Park's Muhammad Awidi, MD, has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors before or after a solid-organ transplant. The study will be featured as an oral abstract during at the American Society of Clinical Oncology Annual Meeting in Chicago.

New research on children diagnosed with acute lymphoblastic leukemia shows that the longer a patient’s BMI falls within the overweight/obese category during treatment, the greater the risk of relapse and the lower the chance of survival.

Roswell Park announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. Four studies that incorporate SurVaxM are currently underway at Roswell Park and other centers nationally.

Roswell Park has been recognized by two national organizations for its excellence as a workplace.